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Conclusion. These data demonstrate impaired stimulatedEndothelial dysfunction in renal transplant recipients main-
and basal NO production in CsA patients, indicating endothe-tained on cyclosporine.
lial dysfunction. This may predispose patients to atherosclerosisBackground. Hypertension is almost universal following re-
and may be involved in the etiology of post-transplant hyper-nal transplantation and may contribute to the already poor
tension.cardiovascular prognosis of this group. Cyclosporine-induced
hypertension is a particular problem and has variously been
attributed to increased sympathetic nerve activity, salt and
water retention, and increased circulating endothelin levels. The introduction of cyclosporine to standard immuno-However, the effects of cyclosporine on the l-arginine/nitric
suppressive protocols in 1984 has greatly improved graftoxide (NO) system in vivo in humans are unknown. In this
survival in renal transplantation [1], but patients con-present study, we examined basal and stimulated NO produc-
tion from the vascular endothelium in cyclosporine-treated tinue to die prematurely of cardiovascular disease. Fig-
renal transplant recipients using the technique of forearm ve- ures from the European Renal Association Registry
nous plethysmography. show an approximate tenfold increase in mortality fromMethods. In study 1, stimulated NO production was assessed
cardiovascular disease in renal transplant recipients com-in 9 cyclosporine-treated renal transplant recipients (CsA), 7
pared with the general population [2]. Hypertension oc-azathioprine-treated renal transplant recipients (AZA), and
12 controls, using carbachol (an endothelium-dependent vaso- curs in approximately 80% of patients following renal
dilator) and sodium nitroprusside (an endothelium-independent transplantation [3] and is likely to play a major role in
vasodilator). In study 2, basal NO production was assessed in 9 the development of cardiovascular disease; however, thecyclosporine-treated patients and 11 controls using l-NMMA
pathophysiology of cyclosporine-induced hypertension(inhibits NO synthase), with norepinephrine as a control vaso-
is unclear.constrictor. Drugs were infused into the nondominant forearm
through a sterile 27-gauge needle, and changes in forearm In keeping with most forms of hypertension, cyclo-
blood flow (FBF) were measured using venous occlusion ple- sporine-induced hypertension involves an increased sys-
thysmography. temic vascular resistance [4]. Several clinical and in vitro
Results. In study 1, sodium nitroprusside caused a similar
studies have suggested a range of possible mechanisms,dose-dependent increase in FBF in all groups. However, the
including sodium retention [5], raised circulating endo-median (range) percentage increase FBF to carbachol (3 mg/min)
thelin levels [6], and altered prostaglandin productionwas markedly reduced in the CsA patients (188.8; 72.5 to 385.1)
compared with AZA patients (378.1; 124.0 to 548.9; P 5 0.042) [7]. Some studies have demonstrated activation of the
and to controls (303.8; 124.8 to 813.3; P 5 0.028). In study 2, sympathetic nervous system [8], while others have not
the maximum percentage reduction in FBF to l-NMMA (4 [9, 10]. In animal studies, cyclosporine increases plasma
mmol/min) was less pronounced in CsA patients (219.5; 24.7
renin activity, while in humans, there is either littleto 263.1) compared with controls (2 39.5; 215.7 to 252.8; P 5
change or a reduction in plasma renin activity [11], al-0.056), and while controls vasoconstricted to the maximum
dose of norepinephrine (240 pmol/min) as expected (226.9; though renin may be inappropriately high for the degree
21.4 to 238.6), CsA patients as a group tended to vasodilate of blood pressure.
(7.9; 236.8 to 92.6; P 5 0.02). Early organ bath work showed that cyclosporine vaso-
constricted smooth muscle preparations, an effect par-
tially blocked by a-adrenoceptor antagonists [12]. MoreKey words: renal transplantation, hypertension, cardiovascular dis-
ease, forearm plethysmography, vascular endothelium. recently, attention has focused on the l-arginine/nitric
oxide (NO) system, with work showing attenuated ace-Received for publication February 17, 1999
tylcholine (NO)-mediated vasodilation in cyclosporine-and in revised form October 6, 1999
Accepted for publication October 12, 1999 treated dogs [13] and rats [14], and a reduction in induc-
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study in humans failed to show any improvement in treated patients and controls were examined further in
study 2.endothelium (NO)-dependent vasodilation after conver-
sion from cyclosporine to azathioprine (AZA) [16].
PlethysmographyThe aim of this study was to examine both basal and
stimulated endothelial NO production in cyclosporine- All studies were performed in a vascular research labo-
ratory maintained at 24 to 268C. The room was sealedtreated renal transplant recipients using the in vivo tech-
nique of forearm strain-gauge plethysmography. and quiet and had dimmed lighting. Subjects lay supine
with arms supported above heart level on foam blocks.
Pediatric cuffs (Hokanson TMC-7; PMS Instruments,
METHODS
Maidenhead, UK) were placed around the wrists and
Subjects inflated to at least 40 mm Hg above systolic blood pres-
sure for three minutes during each recording, to excludeRenal transplant recipients, at least one year post-
transplantation and with stable allograft function, were the hand circulation from the system. Collecting cuffs
(Hokanson SC10) were placed around the upper armsrecruited from the transplant follow-up clinic at the
Western Infirmary (Glasgow, UK). Controls without re- and inflated (40 mm Hg) and deflated in a 15-second
cycle. Rapid cuff inflation was achieved using a Hokan-nal disease were obtained from hospital staff and by
advertisement. All subjects gave written informed con- son AG101 air source, linked to two Hokanson E20 rapid
cuff inflators. Blood pressure was measured at the endsent, and the protocol was approved by the local ethics
committee. of each blood flow recording, using a semiautomatic oscil-
lometric sphygmomanometer (Critikon Dinamap Plus,In study 1, stimulated NO production was assessed in
9 CsA-treated patients, 7 patients on an AZA-based Tampa, FL, USA) placed around the dominant arm,
over the collecting cuff.regime, and 12 controls without renal disease. In study 2,
basal NO production was assessed in 9 CsA-treated pa- The maximal circumference of the forearm was mea-
sured and a mercury-in-silastic strain gauge (Hokansentients and 11 controls. Patients in the cyclosporine-treated
group were maintained on prednisolone (5 to 10 mg/day), forearm set) chosen 2 cm shorter than the circumference.
Strain gauges were calibrated electrically while in posi-AZA (1 to 2 mg/kg/day), and cyclosporine (3 to 5 mg/kg/
day). Patients in the AZA group were maintained on tion using a built-in calibration method.
Under local anesthesia (1 mL 1% lignocaine), a sterileprednisolone (5 to 10 mg/day) and AZA (1 to 2 mg/kg/
day). These patients were initially also treated with 27-gauge dental needle (Terumo, Japan) was inserted
into the brachial artery of the nondominant forearm.cyclosporine, but this was withdrawn at 6- to 12-months
post-transplantation for a variety of reasons, including The needle was connected to an infusion pump using a
modified 16-gauge epidural giving set (Portex, Hythe,hirsutism, gingival hyperplasia, gout, and hypertension.
The patient and control groups were of a similar age UK), and drugs or 0.9% saline was infused throughout
the study at 1 mL/min. Baseline measurements of fore-and sex distribution and had similar smoking habits and
serum cholesterol concentrations. Background charac- arm blood flow (FBF) were obtained at 10-minute inter-
vals for 30 minutes to allow acclimatization to inflationteristics of subjects enrolled into study 1 (stimulated NO
production) are depicted in Table 1, and of those enrolled and deflation of the cuffs. The final baseline reading was
used as the baseline blood flow.into study 2 (basal NO production) are in Table 2. Three
of the controls and six of the cyclosporine-treated pa-
Infusion protocoltients participated in both studies.
Patients were excluded if they were currently anticoag- In study 1, incremental infusions of carbachol (0.1, 0.3,
1.0, 3.0 mg/min) and sodium nitroprusside (0.3, 1.0, 3.0,ulated, had a history of diabetes mellitus, vasculitis, or
myocardial infarction, or were taking anti-anginal medi- 10.0 mg/min) were then commenced, with the order of
drugs randomized between subjects. In study 2, norepi-cation or statins. Patients were also excluded if they had
severe hypertension such that antihypertensive drugs nephrine was infused first (60, 120, 240 pmol/min) fol-
lowed by NG-monomethyl-l-arginine (l-NMMA; 1, 2, 4could not be withheld prior to the study.
All subjects were studied in the morning after an over- mmol/min) in view of its long half-life. There was a 30-
minute washout period with 0.9% saline between drugnight fast and were asked to omit aspirin for seven days
and antihypertensive medication for at least 48 hours infusions. The protocol is illustrated in Figure 1. All drug
solutions were prepared in 0.9% saline in the sterilebefore the study. Immunosuppressive drugs were taken
normally on the day of study. Subjects were asked to pharmacy productions unit in the hospital. Each drug
was infused for seven minutes with FBF measurementsavoid caffeine and alcohol and to refrain from smoking
for at least 12 hours prior to the study. taken from minutes 3 through 6, and blood pressure
was recorded in the seventh minute. During each drugAs stimulated endothelial NO production was normal
in AZA-treated patients in study 1, only cyclosporine- infusion, several FBF measurements were made; the
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Table 1. Background characteristics for patients and controls in study 1
Control AZA CsA P valuea P valueb
Male (total) 8 (12) 6 (7) 7 (9) 0.950 —
Smoker N 7 4 4 0.950 —
Age years 40 (25–51) 45 (33–51) 36 (24–55) 0.681 —
Urea mmol/L 4.4 (2.9–6.6) 6.9 (4.6–10.4) 7.6 (5.7–12.5) ,0.001 0.210
Creatinine lmol/L 85 (57–108) 133 (80–223) 143 (111–215) 0.001 0.837
Glucose mmol/L 4.7 (4.3–5.6) 4.4 (3.8–6.4) 4.7 (4.3–6.5) 0.805 —
Cholesterol mmol/L 5.3 (3.5–6.6) 5.4 (3.6–7.4) 5.6 (3.7–9.3) 0.360 —
Triglyceride mmol/L 1.1 (0.6–3.1) 1.4 (0.5–2.8) 2.1 (0.6–5.4) 0.242 —
Hemoglobin g/dL 14.5 (12.4–15.6) 13.6 (11.0–15.6) 12.9 (10.6–14.7) 0.020 0.351
SBP mm Hg 124 (104–158) 130 (106–155) 158 (127–184) 0.007 0.029
DBP mm Hg 71 (50–75) 80 (70–91) 89 (70–99) 0.002 0.054
FBF mL · 100 mL21 2.95 (1.68–4.98) 2.40 (1.75–3.88) 2.80 (1.67–7.84) 0.474 —
Total RRT months — 232 (112–348) 108 (51–231) — 0.023
Months since Tx — 129 (83–312) 48 (14–216) — 0.142
CCBs N — 1 6 — 0.200
b blockers N — 2 3 — 0.900
Aspirin N — 1 1 — 0.900
Trough CsA level nmol/L — — 82 (41–121) — —
Results are expressed as median (range).
Abbreviations are: FBF, baseline forearm blood flow in infused arm; RRT, renal replacement therapy; CCBs, calcium channel blockers; SBP, systolic blood
pressure; DBP, diastolic blood pressure; Tx, transplant.
aRepresents Kruskall-Wallis or chi-square comparison between three groups
bRepresents Mann-Whitney or chi-square test between CsA and AZA
Table 2. Background characteristics for patients and Laboratory evaluation
controls in study 2
Prior to each plethysmography session, a 21-gauge
Control CsA P value cannula was inserted into the dominant arm, and blood
Male (total) 11 (11) 9 (9) — was drawn after a 20-minute period of supine rest. Thirty
Smoker N 5 4 0.980
milliliters of blood were drawn into ethylenediaminetet-Age years 38 (28–42) 36 (24–55) 0.492
Urea mmol/L 4.5 (2.8–6.7) 8.2 (6.0–11.7) ,0.001 raacetic acid (EDTA), lithium heparin, or plain tubes,
Creatinine lmol/L 87 (73–100) 157 (90–164) ,0.001 spun, and frozen immediately. In addition to standard
Glucose mmol/L 5.0 (4.4–5.2) 5.2 (4.1–6.5) 0.182
hematological and biochemical analyses, assays wereCholesterol mmol/L 5.0 (3.1–6.8) 5.9 (3.6–6.5) 0.604
Triglyceride mmol/L 1.2 (0.8–1.9) 2.0 (0.8–5.4) 0.211 performed for renin [19], norepinephrine [20], and for
Hemoglobin g/dL 13.9 (12.4–15.5) 13.2 (10.5–13.6) 0.019 endothelin-1 using a commercially available kit (Cozart
SBP mm Hg 125 (101–144) 146 (108–169) 0.056
Bioscience, UK).DBP mm Hg 72 (56–79) 84 (64–95) 0.002
FBF mL · 100 mL21 2.82 (1.70–5.20) 3.06 (1.40–5.00) 0.849
Total RRT months — 65 (108–244) — Statistical comparison
Months since Tx — 20 (51–216) —
All results are expressed as median (range) unlessCCBs N — 7 —
b blockers N — 3 — otherwise specified. Comparison between groups is by
Aspirin — 2 — multivariate analysis of variance with repeated measures.Trough CsA level
When significant, post hoc analyses were performed bynmol/L — 96 (37–161) —
Mann–Whitney U to compare individual groups at eachResults are expressed as median (range). The comparison is by Mann-Whitney
or chi-square test. drug dose level. The statistical significance was defined
at the 5% level.
All statistics were performed using SPSS package for
Windows, version 7.0.
mean of the final five readings was taken as the FBF
achieved for each dose of drug.
RESULTSForearm blood flow was expressed as mL blood flow
min21 · 100 mL21 forearm [17]. Bilateral FBF measure- The neurohumoral data from studies 1 and 2 are de-
ments were made, and the results were expressed as a tailed in Tables 3 and 4, respectively. In study 1, there
ratio of infused:noninfused arm, as this method is more was a trend toward higher endothelin levels in patients
reproducible than unilateral plethysmography [18] and compared with controls. This was significant for AZA-
corrects for background variation in FBF. The response treated patients (0.48 fmol/mL; range 0.10 to 1.15) com-
to a particular drug dose was calculated as the percentage pared with controls (0.19; 0.01 to 0.49; P 5 0.022). Renin
levels were similar for all groups studied; however, therechange in FBF ratio from baseline.
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Fig. 1. Infusion protocol for plethysmography. Each dose of drug was infused for seven minutes. Saline or drugs (dissolved in saline) were infused
at 1 mL/min for the duration of the study.
Table 3. Neurohumoral data for study 1
Control AZA CsA P valuea P valueb P valuec
Endothelin-1 fmol/mL 0.19 (0.01–0.49) 0.48 (0.1–1.15) 0.36 (0.18–2.1) 0.019 0.068 0.397
Renin uU/mL 20 (2–44) 27 (16–74) 20 (6–57) 0.104 0.840 0.281
Norepinephrine nmol/L 1.15 (0.01–4.20) 0.30 (0.01–5.30) 0.05 (0.01–4.30) 0.596 0.238 0.463
Results are expressed as median (range). Statistical comparison is by Mann-Whitney test.
aBetween control and AZA
bBetween control and CsA
cBetween AZA and CsA
Table 4. Neurohumoral data from study 2
Control CsA P value
Endothelin-1 fmol/mL 0.12 (0.01–0.30) 0.13 (0.01–0.30) 0.439
Renin uU/mL 12.0 (6.0–28.0) 14.0 (7.0–56.0) 0.385
Noradrenaline nmol/L 0.70 (0.01–1.90) 0.30 (0.01–1.00) 0.558
Results are expressed as median (range), and comparison is by Mann-Whitney
test.
was a trend toward lower norepinephrine levels in CsA
Fig. 2. Dose–response curves for infusion of sodium nitroprussidepatients compared with AZA patients and controls.
(study 1), comparing responses in controls (r), CsA-treated (m), and
Results for study 1 are illustrated in dose–response azathioprine-treated (j) renal transplant recipients. The results are
curve form, with results for infusion of sodium nitroprus- expressed as mean 6 SEM.
side (SNP) in Figure 2 and for carbachol in Figure 3. All
three groups vasodilated similarly to SNP (P 5 0.985 by
multivariate analysis of variance; MANOVA) demon-
cyclosporine group (188.8; 72.5 to 385.0; % change FBFstrating that endothelium-independent vasodilation is
ratio) compared with controls (303.8; 124.8 to 813.3; P 5comparable between groups. However, vasodilation to
0.028) and to the AZA group (378.1; 124.0 to 548.9; P 5carbachol (Fig. 3) was attenuated in the cyclosporine-
0.042).treated patients (P 5 0.008, MANOVA) with a signifi-
cant reduction in response to 3 mg/min carbachol in the In study 2, the response to infusion of l-NMMA is
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Fig. 3. Dose–response curves for infusion of carbachol (study 1), com-
Fig. 5. Dose–response curves for infusion of norepinephrine (study 2),paring responses in controls (r), CsA-treated (m), and azathioprine-
comparing responses in controls (j) and CsA-treated (r) renal trans-treated (j) renal transplant recipients. The results expressed as mean 6
plant recipients. The results are expressed as mean 6 SEM (P 5 0.16,SEM. *P , 0.05
MANOVA). *P , 0.05
lated normally to SNP (NO donor), but exhibited attenu-
ated vasodilation to the muscarinic agonist carbachol.
This pattern suggests impaired stimulated endothelial
NO production. In study 2, the cyclosporine-treated
group vasoconstricted less well to the NO synthase inhib-
itor l-NMMA, suggesting reduced basal endothelial NO
production. The results of both studies indicate endothe-
lial dysfunction in cyclosporine-treated renal transplant
recipients.
This is unlikely to represent the effects of renal trans-
Fig. 4. Dose–response curves for infusion of L-NMMA (study 2), com- plantation itself, as AZA-treated patients had preservedparing responses in controls (j) and CsA-treated (r) renal transplant
stimulated NO production. Neither is it likely to reflectrecipients. The results are expressed as mean 6 SEM.
years of uremia prior to transplantation, as the AZA
group had a longer total time on renal replacement ther-
apy (Table 1). Endothelial dysfunction has been demon-
illustrated in Figure 4. There was a graphical trend to- strated in several conditions, including hypercholesterol-
ward reduced vasoconstriction in the cyclosporine group emia [21], cigarette smoking [22], diabetes mellitus [23],
(overall MANOVA, P 5 0.378), with the difference bor- and cardiac failure [24]. In our study, groups were matched
dering on statistical significance at 4 mmol/min l-NMMA for smoking habit and total cholesterol, although blood
[239.4 (215.7 to 252.8) for controls vs. 219.5 (24.7 to pressure was higher in the cyclosporine group. The ef-
263.1) for CsA; P 5 0.053 by Mann–Whitney test]. The fects of hypertension on endothelial function are less
results for the infusion of norepinephrine are illustrated clear, with one large study showing preserved endothe-
in Figure 5. Cyclosporine patients as a group tended to lium-dependent vasodilation [25], and one similarly large
vasodilate, while controls vasoconstricted as expected study showing abnormal endothelium-dependent vaso-
(P 5 0.016, MANOVA). The maximum % change FBF
dilation in essential hypertension [26]. It is therefore
ratio for 240 pmol/min norepinephrine was 227.0 (20.4
possible that the endothelial dysfunction is related toto 238.6) for controls compared with 7.9 (236.8 to 92.6)
hypertension per se, although the study by Cockcroft et alfor CsA-treated patients (P 5 0.02, Mann–Whitney test).
failed to show endothelial dysfunction in essential hyper-Pulse and blood pressure did not change significantly
tension [25]. Another “unmatched” variable was the tri-throughout the studies, as the doses of drugs infused
gylceride level, although studies in severe hypertriglycer-were chosen to exert only local effects in the forearm.
idemia have shown preserved endothelial function [27].
It is thus possible that the reduced endothelial NO
DISCUSSION production in the cyclosporine-treated patients is a direct
effect of cyclosporine therapy, a theory supported byThis study was designed to examine the effects of
previous in vitro organ-bath work, which demonstratedcyclosporine treatment on basal and stimulated endothe-
reduced production of NO from large arteries after short-lial NO production in humans in vivo. In study 1,
cyclosporine-treated renal transplant recipients vasodi- term exposure to cyclosporine [28]. As NO synthase is
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Reprint requests to Dr. Scott Morris, Renal Unit, Western Infirmary,a calcium-calmodulin–dependent enzyme, cyclosporine
Dumbarton Rd, Glasgow G11 6NT, Scotland, United Kingdom.may directly inhibit the production of NO by inhibition
of calcineurin. This may be one potential mechanism
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